比较多种生物标志物对缺血性和非缺血性病因急性心力衰竭患者死亡率的预测价值。
Comparison of multiple biomarkers for mortality prediction in patients with acute heart failure of ischemic and nonischemic etiology.
机构信息
Department of Cardiology, Taian City Central Hospital, Tai'an, 271000, PR China.
出版信息
Biomark Med. 2018 Nov;12(11):1207-1217. doi: 10.2217/bmm-2018-0123. Epub 2018 Nov 30.
AIM
To investigate the prognosis of soluble ST2 (sST2), galectin-3 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for death related to ischemic and nonischemic etiology of acute heart failure (HF).
METHODS
The associations between biomarkers and death were determined in 1020 patients admitted to hospital with acute HF.
RESULTS
During 1-year follow-up, 162 patients died. Multivariable regression analysis showed that the hazard ratios of sST2 and NT-proBNP for 1-year all-cause death was similar and remained significant between ischemic and nonischemic HF patients. However, galectin-3 was not significantly associated with death when sST2 and NT-proBNP were incorporated into model in ischemic HF patients.
CONCLUSION
There is no etiology dependent prognostic ability of NT-proBNP or ST2 in patients with acute HF, but for galectin-3 there is no added prognostic ability in ischemic HF.
目的
研究可溶性 ST2（sST2）、半乳糖凝集素-3 和 N 末端 B 型利钠肽前体（NT-proBNP）对缺血性和非缺血性病因引起的急性心力衰竭（HF）相关死亡的预后价值。
方法
在因急性 HF 住院的 1020 例患者中，确定了生物标志物与死亡之间的相关性。
结果
在 1 年的随访期间，有 162 例患者死亡。多变量回归分析显示，sST2 和 NT-proBNP 对 1 年全因死亡的风险比相似，在缺血性和非缺血性 HF 患者中仍然显著。然而，当将 sST2 和 NT-proBNP 纳入缺血性 HF 患者的模型时，半乳糖凝集素-3 与死亡无显著相关性。
结论
在急性 HF 患者中，NT-proBNP 或 ST2 与病因无关，无预后能力，但在缺血性 HF 中，半乳糖凝集素-3 无额外的预后能力。
Zotero 插件